Exploiting topology-directed nanoparticle disassembly for triggered drug delivery by Arno, M.C. et al.
Accepted Manuscript
Exploiting topology-directed nanoparticle disassembly for triggered drug delivery
Maria C. Arno, Rebecca J. Williams, Panagiotis Bexis, Anaїs Pitto-Barry, Nigel Kirby,
Andrew P. Dove, Rachel K. O'Reilly
PII: S0142-9612(18)30497-6
DOI: 10.1016/j.biomaterials.2018.07.019
Reference: JBMT 18762
To appear in: Biomaterials
Received Date: 11 March 2018
Revised Date: 26 June 2018
Accepted Date: 10 July 2018
Please cite this article as: Arno MC, Williams RJ, Bexis P, Pitto-Barry Anaї, Kirby N, Dove AP, O'Reilly
RK, Exploiting topology-directed nanoparticle disassembly for triggered drug delivery, Biomaterials
(2018), doi: 10.1016/j.biomaterials.2018.07.019.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
Exploiting topology-directed nanoparticle disassembly for triggered drug 
delivery 
 
Maria C. Arno‡,a,b Rebecca J. Williams‡,a Panagiotis Bexis,a,b Anaїs Pitto-Barry,a Nigel 
Kirby,c Andrew P. Dovea,b* and Rachel K. O’Reillya,b* 
 
aUniversity of Warwick, Department of Chemistry, Gibbet Hill Road, Coventry CV4 7AL, 
UK. 
bUniversity of Birmingham, School of Chemistry, Edgbaston, Birmingham, B15 2TT, UK. 
cAustralian Synchrotron, 800 Blackburn Road, Clayton, Victoria 3168, Australia. 
‡ These authors contributed equally. 
*E-mail: r.oreilly@bham.ac.uk; a.dove@bham.ac.uk 
 
KEYWORDS: graft copolymers, cyclic polymers, disulfide linker, acetal linker, topology-
controlled particle disassembly  
 
Abstract 
The physical properties of cyclic and linear polymers are markedly different; however, there 
are few examples which exploit these differences in clinical applications. In this study, we 
demonstrate that self-assemblies comprised of cyclic-linear graft copolymers are significantly 
more stable than the equivalent linear-linear graft copolymer assemblies. This difference in 
stability can be exploited to allow for triggered disassembly by cleavage of just a single bond 
within the cyclic polymer backbone, via disulfide reduction, in the presence of intracellular 
levels of L-glutathione. This topological effect was exploited to demonstrate the first example 
of topology-controlled particle disassembly for the controlled release of an anti-cancer drug 
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in vitro.  This approach represents a markedly different strategy for controlled release from 
polymer nanoparticles and highlights for the first time that a change in polymer topology can 
be used as a trigger in the design of delivery vehicles. We propose such constructs, which 
demonstrate disassembly behavior upon a change in polymer topology, could find application 
in the targeted delivery of therapeutic agents.  
 
Introduction 
Polymer topology can exert significant influence over the properties and potential 
applications of a polymeric material. Among the range of accessible topologies, cyclic 
polymers have drawn considerable attention as a consequence of the unique behavior they 
exhibit in comparison to their linear counterparts.1-8 While significant progress has been 
made towards understanding these fundamental property differences, there are comparatively 
few reports that exploit these differences in specific applications. Nevertheless, polymers 
with a cyclic topology have shown great promise as potential drug and gene delivery 
vehicles, often exhibiting greater efficacy, e.g. higher gene transfection efficiencies,9-10 
longer in vivo circulation times,11 and higher cancer cell uptake,11-13 than their linear 
counterparts. Furthermore, amphiphilic cyclic polymers display markedly different self-
assembly behavior compared to linear amphiphilic polymers,6 with cyclization shown to 
affect the dimensions,14 morphology,15-17 temperature and salt tolerance,18-19 and 
degradation14 of polymer self-assemblies.  
 The selective delivery of therapeutic compounds from polymer nanoparticles shows 
promise for the treatment of cancer and other diseases. Controlled release of a compound at 
the site of action is desirable to maximize efficacy, minimize side-effects and frequency of 
administration. As such, triggered particle disassembly has been studied as a means to control 
payload release.20-21 Whilst numerous stimuli including temperature22-23 and light24 have been 
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exploited to trigger particle disassembly, these are generally not suitable for in vivo 
applications given the inability to precisely control these factors within the cell. Thus, 
polymer degradation is the generally favored mechanism for in vivo particle disassembly and 
cargo release. Degradation may be selective or non-selective, for example, the hydrolysis of 
ester linkages is non-specific and occurs under all physiological conditions, while the 
reduction of disulfide bonds in the presence of the biological reducing agent L-glutathione 
(GSH) occurs primarily in intracellular environments as a consequence of the 100-fold 
increase of GSH in intracellular environments compared to extracellular environments.25-26 
Indeed, the difference in intracellular and extracellular GSH concentration has been elegantly 
exploited for the disassembly of polymeric constructs through the cleavage of disulfide 
crosslinks, which has been coupled to the release of a range of payloads.27-28 However, in all 
instances of particle disassembly through degradation or breakage of crosslinks, 
consideration must be given to the resulting degradation products, which may differ 
significantly in chemical structure, molar mass, solubility, and therefore toxicity and 
retention, compared to the original polymer.  
To overcome this limitation, we designed a new class of responsive constructs that 
can undergo a topological change and disassembly process in response to a reducing 
(intracellular) environment. We report the first instance of topology-controlled particle 
disassembly in vitro, triggered by a switch in polymer topology from cyclic to linear, where 
the disassembled and original polymers vary only in topology. Inspired by the observation 
that self-assemblies of cyclic-linear graft copolymers (with a cyclic core and linear arms) 
were significantly more stable than equivalent linear-linear graft copolymer assemblies (with 
a linear core and linear arms), we hypothesized that this topology effect could be exploited to 
trigger particle disassembly through incorporation of a cleavable disulfide linkage in the 
cyclic polymer backbone. Upon disulfide cleavage, the cyclic-linear graft copolymer 
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assembly switches to an unstable linear graft copolymer assembly, which disassembles. 
Importantly, disulfide cleavage and subsequent particle disassembly can be triggered in the 
presence of intracellular levels of the cellular reducing agent L-glutathione. To demonstrate 
that the topology switch is independent from the cleavable linker selected, an acid-sensitive 
acetal linker was incorporated in the cyclic polymer structure, and the topology-directed 
disassembly was triggered by acidic pH. This approach represents a significant breakthrough 
in the development of new strategies for in vivo particle disassembly and the selective 
delivery of therapeutic agents, as well as expanding the potential applications of cyclic 
polymers.  
 
Materials and methods 
Materials 
1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) was dried over CaH2, distilled and stored 
under inert atmosphere. 1,4-butanediol and 1,3-propanediol were dried and stored over 3 Å 
molecular sieves. RAFT CTA-functional carbonate and 5-methyl-5-ethoxycarbonyl-1,3-
dioxan-2-one monomers were synthesized as previously reported and dried over 3 Å 
molecular sieves in dry CH2Cl2.29-30 4-pentynoic anhydride was prepared according to the 
literature.13,31 AIBN (2,2'-azo-bis(isobutyronitrile)) was recrystallized twice from methanol 
and stored in the dark at 4 ˚C. CH2Cl2 was purified over Innovative Technology SPS alumina 
solvent columns and degassed before use. Nanopure water with a resistivity of 18.2 MΩ·cm 
was prepared using a Millipore Simplicity UV ultrapure water purification system. All other 
solvents and chemicals were obtained from Sigma-Aldrich or Fisher Scientific and used as 
received. For the biological studies, A549 cells were purchased from Public Health England, 
UK. F-12K (Kaighn's) medium was purchased from Gibco, fetal bovine serum (FBS) was 
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acquired from Sigma-Aldrich, penicillin/streptomycin (pen/strep) antibiotic solution was 
acquired from Fisher Scientific. 
Synthesis of RAFT CTA-functional polycarbonate  
1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) (38 mg, 0.25 mmol) was added to a solution of 
the appropriate equivalents of RAFT CTA-functional carbonate (1 g, 2.5 mmol), 5-methyl-5-
ethoxycarbonyl-1,3-dioxan-2-one (0.47 g, 2.5 mmol) and 1,4-butanediol (0.018 g, 0.2 mmol) 
or 1,3-propanediol (0.011 g, 0.2 mmol) in dry CH2Cl2 (20 mL)  and stirred at room 
temperature. After the desired amount of time the polymerization was quenched by the 
addition of Amberlyst 15 H+ ion exchange resin. The resin was removed by filtration, the 
solution concentrated and the polymer precipitated in cold diethyl ether. The unreacted 
monomers and residual DBU were removed by column chromatography (silica, 100% 
CH2Cl2, then 100% ethyl acetate, yield = 65%).32 1H NMR (400 MHz, CDCl3, ppm): δ = 
7.31-7.26 (m, 4Hbackbone-1, Ar), 5.11 (m, 2Hbackbone-1, OCH2Ar), 4.59 (m, 2Hbackbone-1, SCH2Ar), 
4.28 (m, 8Hbackbone-1+2, C=OOCH2C(CH3)CH2O), 4.17 (m, 2Hbackbone-2, OCH2CH3), 4.11 (m, 
4Hend-group, OCH2CH2), 3.37 (m, 2Hbackbone-1, SCH2CH3), 1.73 (m, 4Hend-group, OCH2CH2), 1.35 
(m, 3Hbackbone-1, SCH2CH3), 1.24 (m, 6Hbackbone-1+2, CCH3), 1.21 (m, 3Hbackbone-2, OCH2CH3). 
SEC (CHCl3 + 0.5% NEt3, PS standards): Mn (SEC) = 6.0 kg mol-1, ĐM = 1.18. 
End-group functionalization 
Pyridine (0.12 g, 1.5 mmol) was added to a solution of RAFT CTA-functional polycarbonate 
(1 g, 0.15 mmol), 4-pentynoic anhydride32 (0.88 g, 4.5 mmol) and DMAP (55 mg, 0.45 
mmol) in dry CH2Cl2 (30 mL) and stirred under nitrogen for 36 h. The solution was washed 
with saturated NaHSO4 (2 × 50 mL) and saturated NaHCO3 (2 × 50 mL) and the organic 
layer dried over MgSO4. Solvent was removed in vacuo, the polymer residue dissolved in the 
minimum amount of CHCl3 and precipitated into petroleum ether 40-60 ˚C three times (Yield 
= 82%).32 1H NMR (400 MHz, CDCl3, ppm): δ = 7.31-7.26 (m, 4Hbackbone-1, Ar), 5.11 (m, 
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2Hbackbone-1, OCH2Ar), 4.59 (m, 2Hbackbone-1, SCH2Ar), 4.28 (m, 8Hbackbone-1+2, 
C=OOCH2C(CH3)CH2O), 4.17 (m, 2Hbackbone-2, OCH2CH3), 4.11 (m, 4Hend-group, OCH2CH2), 
3.87 (m, 2Hbackbone-1, SCH2CH3), 2.55 (m, 4Hend-group, CH2CH2CCH), 2.50-2.42 (m, 4Hend-group, 
CH2CH2CCH), 1.97 (m, 2Hend-group, CH), 1.73 (m, 4Hend-group, OCH2CH2), 1.34 (m, 3Hbackbone-
1, SCH2CH3), 1.24 (m, 6Hbackbone-1+2, CCH3), 1.22 (m, 3Hbackbone-2, OCH2CH3). SEC (CHCl3 + 
0.5% NEt3, PS standards): Mn (SEC) = 7.4 kg mol-1, ĐM = 1.17. 
Synthesis of azides small molecules 
Caution: Small organic azides are potentially explosive and must be handled with care, 
particularly in concentrated forms and/or in large quantities. Keep away from sources of heat, 
pressure, light, shocks and strong acids. Bis-(azidoethyl)disulfide was prepared according to 
literature procedures (Yield: 80%).13,33 1H NMR (400 MHz, CDCl3, ppm): δ = 3.59 (t, 4H, 
N3CH2, 3JH-H = 6.7 Hz), 2.86 (t, 4H, SCH2, 3JH-H = 6.7 Hz). 13C NMR (100 MHz, CDCl3, 
ppm): δ = 50.0 (N3CH2), 37.7 (SCH2). 
 1,8-diazidooctane was prepared according to literature procedures (Yield: 78%).34-35 
1H NMR (300 MHz, CDCl3, ppm): δ = 3.25 (t, 4H, N3CH2, 3JH-H = 6 Hz), 1.64-1.55 (m, 4H, 
N3CH2CH2), 1.34 (m, 8H, CH2). 13C NMR (300 MHz, CDCl3, ppm): δ = 52.5 (N3CH2), 29.1 
(N3CH2CH2), 28.9 (CH2), 26.7 (CH2). 
 2,2-bis(2-azidoethoxy)propane was prepared as described below. Imidazole-1-
sulfonyl azide hydrochloride was prepared according to a literature procedure.36 2-[1-(2-
Amino-ethoxy)-1-methyl-ethoxy]-ethylamine (AEE) was prepared following a literature 
procedure.37 Imidazole-1-sulfonyl azide hydrochloride (2.6 g, 12.40 mmol) was then added to 
a solution of AEE (1 g, 6.17 mmol) in MeOH (20 mL). Potassium carbonate (2.6 g, 19 mmol) 
and copper(II) sulfate pentahydrate (0.015 g, 0.062 mmol) were then added to the mixture. 
The solution was stirred at room temperature overnight, then concentrated and diluted with 
water (20 mL). The product was then extracted with EtOAc (100 mL), washed with brine (3 
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× 50 mL), and dried over MgSO4. Flash chromatography was used for purification (90:10 
hexane:EtOAc) to obtain a clear viscous liquid (Yield: 63%).  1H NMR (300 MHz, CDCl3, 
ppm): δ = 3.64 (t, 4H, N3CH2, 3JH-H = 6 Hz), 3.36 (t, 4H, N3CH2CH2O, 3JH-H = 6 Hz), 1.39 (s, 
6H, CH3). 13C NMR (300 MHz, CDCl3, ppm): δ = 100.61 (C), 60.17 (N3CH2CH2O), 51.1 
(N3CH2), 24.76 (CH3). Mass = [M+ + Na+] 236.7. 
Cyclization via the copper-catalyzed azide-alkyne cycloaddition 
A solution of N,N,N’,N’’-pentamethyldiethylenetriamine (PMDETA) in toluene (0.15 
g, 0.9 mmol, 0.002 M) was bubbled with nitrogen for 1 h. Cu(I)Br (0.12 g, 0.83 mmol) was 
added and the solution bubbled for a further 30 min. In a separate ampoule a solution of 
alkyne terminated RAFT CTA-functional polycarbonate (0.06 g, 0.008 mmol) and a diazide 
linker (1.7 mg, 0.008 mmol) in toluene (1 mM) was degassed via 3 freeze-pump-thaw cycles. 
The degassed solution was then transferred into a gas-tight glass syringe and added at a rate 
of 0.3 mL/h to the solution of PMDETA and Cu(I)Br whilst stirred under nitrogen. After 
complete addition the solution was stirred for a further 3 h, then washed with saturated 
NaHCO3 (3 × 50 mL) and brine (3 × 50 mL) and the organic layer dried over MgSO4. 
Toluene was removed in vacuo and the polymer residue was dissolved in CH2Cl2 (100 mL) 
and stirred in the presence of Cuprisorb beads overnight. The beads were removed via 
filtration and the polymer was precipitated into petroleum ether 40-60 ˚C (50 mL) three times 
(Yields = 45-51%). 1H NMR (400 MHz, CDCl3, ppm): δ = 7.31-7.25 (m, 4Hbackbone-1, Ar), 
5.12 (m, 2Hbackbone-1, OCH2Ar), 4.59 (m, 2Hbackbone-1, SCH2Ar), 4.28 (m, 8Hbackbone-1+2, 
C=OOCH2C(CH3)CH2O), 4.17 (m, 2Hbackbone-2, OCH2CH3), 4.12 (m, 4Hend-group, OCH2CH2), 
3.37 (m, 2Hbackbone-1, SCH2CH3), 3.14-2.59 (m, 12Hend-group, CH2SSCH2 + CH2CH2CCH + 
CH2CH2CCH), 1.73 (m, 4Hend-group, OCH2CH2), 1.35 (m, 3Hbackbone-1, SCH2CH3), 1.24 (m, 
6Hbackbone-1+2, CCH3), 1.22 (m, 3Hbackbone-2, OCH2CH3). SEC (CHCl3 + 0.5% NEt3, PS 
standards): Mn (SEC) = 6.2 kg mol-1, ÐM = 1.16. 
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General procedure for RAFT polymerizations 
The appropriate equivalents of RAFT CTA-functional cyclic (0.05 g, 0.008 mmol) or linear 
polycarbonate (0.05 g, 0.007 mmol), AIBN (0.5 eq. to total RAFT CTA groups) and 4-
Acryloylmorpholine (0.76 g, 5.4 mmol) were loaded into a dry ampoule and dissolved in 
CHCl3 (1.5 mL). The reaction mixture was degassed via 4 freeze-pump-thaw cycles and 
refilled with nitrogen. The polymerization was initiated by immersion of the ampoule into an 
oil bath at 70 ˚C. After the desired length of time the polymerization was quenched by 
immersion of the ampoule in liquid nitrogen. Monomer conversions were kept below 50% to 
minimize graft-graft coupling. 
General procedure for particle preparation  
Assemblies were prepared using the solvent switch method or the direct dissolution 
method. In the first case, the relevant polymer was dissolved in THF at 10 mg/mL. 18.2 
MΩ·cm water (20 mL) was added to the stirred solution via a peristaltic pump at a rate of 0.6 
mL/h. After complete water addition, THF was removed via exhaustive dialysis (6-8 kDa 
MWCO) against 18.2 MΩ·cm water for 3 days to yield a final concentration of ca. 0.5 
mg/mL. No loss of polymer was observed after dialysis under these conditions. In the direct 
dissolution method, the relevant polymer was dissolved in 18.2 MΩ·cm water to reach the 
desired concentration (from 0.25 to 2 mg/mL) and analysed directly after.  
General procedure for particle preparation via thin film hydration 
The relevant polymer was dissolved in CHCl3 (1 mg/mL) in a round bottom flask.  
CHCl3 was removed in vacuo to leave a thin polymer film coating the inside of the flask. 18.2 
MΩ·cm water was carefully added down the side of the flask to prevent disruption of the 
polymer film, which was left to hydrate for 16 h to give a final polymer concentration of ca. 
0.5 mg/mL. 
Determination of cmc via fluorescence spectroscopy 
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73 µL of a stock solution of pyrene in acetone (2.47 × 10-6 M) was added to several 
vials and the acetone subsequently evaporated. The cyclic and linear assemblies were 
prepared via direct dissolution in 18.2 MΩ·cm water, with concentrations from 0.0003 to 2 
mg/mL. 300 µL of each polymer solution was added to a pyrene containing vial and stirred 
overnight to give a final pyrene concentration of 6 × 10-7 M. Excitation spectra were recorded 
in the range λex = 300-375 nm and λem = 390 nm. A clear shift in the excitation spectra of 
pyrene of the excitation maxima from ca. 339 to 335 nm is observed when pyrene enters a 
hydrophobic environment. Comparison of the intensity of these two signals (I339/I334.5) over a 
range of polymer concentrations allows determination of the cmc; where the cmc was taken 
as the inflection point in the plot of I339/I334.5 vs polymer concentration. 
Encapsulation of small molecules 
The relevant polymer was dissolved in 2 mL of DMSO at a concentration of 10 mg/mL. 20 
wt% of the small molecule (BODIPY-FL, Camptothecin) was then added to the solution and 
stirred for 30 min to achieve a homogeneous solution. 20 mL of 18.2 MΩ·cm water was then 
added to the solution and left to stir overnight. Exhaustive dialysis (6-8 kDa MWCO) against 
18.2 MΩ·cm water for 3 days was then used to remove any un-encapsulated dye/drug. The 
drug loading was optimized using different feeding ratios (5, 10, 20, 40% w/w of 
drug:polymer) and it was observed that a feeding ratio of 20% would achieve the highest 
encapsulation efficiency (70%). Encapsulation efficiency (EE) was calculated using the 
following equation:  
 = 	
		
					ℎ	
		
				
× 100 
where the amount of drug was measured via fluorescence spectroscopy. Cyclic or linear 
assemblies were dissolved in DMSO to a concentration of 1 mg/mL. The drug loading was 
calculated for all the cyclic polymers independently and for the linear 2 polymer by 
fluorescence measurements using a plate reader. The solution of assemblies (40 µL) and 
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DMSO (10 µL) were pipetted into a black flat bottom 96 well plate and read on a BMG 
Labtech FLUOstar OPTIMA plate reader (λex = 370 nm λem = 428 nm). Three samples were 
read and the fluorescence averaged. Control curves were constructed by dissolving blank 
assemblies as described above and adding known amounts of drug. 
Drug release studies 
The relevant polymer (2 mL, 1 mg/mL) was incubated with either 10 µM or 10 mM of L-
glutathione and the vial was placed in a shaking incubator (60 rpm) at 37 ºC. Time points 
were taken every 2 hours, up to 16 h, and the drug concentration was measured using a 
Spectrofotometer FS5 by Edinburgh Instruments (λex = 370 nm λem = 428 nm). 
Cell viability studies 
A549 cells were cultured in F-12K (Kaighn's) medium with the addition of 10% FBS 
and 1% pen/strep at 37 ˚C, 5% CO2. For the viability experiments, cells were seeded on 24 
wells plates at a seeding density of 10000 cells/mL and let adhere and proliferate for 72 h. 
Culture medium was then replaced with an increasing concentration of linear or cyclic 
assemblies (from 0 to 2 mg/mL), and linear or cyclic assemblies encapsulating camptothecin 
(from 0 to 250 nM of camptothecin in the case of cyclic assemblies and from 0 to 7 nM in the 
case of linear assemblies). Briefly, the cyclic polymers (20 mg) were dissolved in DMSO (2 
mL), then camptothecin (4 mg) was added. After 30 min. under stirring 18 mL of water was 
added to the solution, which was then dialysed to remove DMSO. 20 mL of the particles 
solution was obtained after dialysis, with a drug loading of 0.14 mg of camptothecin per mg 
of polymer (2.8 mg camptothecin per 20 mg of polymer and therefore 0.8 × 10-5 mols and 0.4  
× 10-3 M). This solution was further diluted (0.4 × 10-4 M) in cell culture medium and this 
was used as a stock solution for the camptothecin concentration range used in the cell studies.  
Experiments were performed in triplicate, seeding equal number of cells on three different 
wells and analysing the viability data from each well. Time points were taken at 24 and 72 h 
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of incubation, after removing the polymer solutions and washing the wells with PBS (3 × 1 
mL). Viability was assessed by counting the living cells in each well after trypsinization. 
Specifically, each well was incubated with 0.5 mL of trypsin for 5 min at 37 ˚C, 5% CO2. 
Trypsin was then diluted with culture medium (1:1) and cells were centrifuged at 2000 rpm 
for 5 min to obtain a pellet. The cell pellet was then re-dispersed in fresh medium (1 mL), and 
50 µL of this solution diluted 1:1 with trypan blue. 10 µL of the cell solution was then placed 
in each counting chamber of a haemocytometer and the total number of cells was obtained 
using a Countess II FL Automated Cell Counter. Cell viability is expressed as a percentage 
against the control (polymer concentration = 0 mg/mL). PrestoBlue cell proliferation assay 
was also used to assess the cytotoxicity of the cyclic and linear polymers, following the 
suppliers’ instructions. However it was observed that cyclic 1i was interfering with the assay, 
which is sensitive to thiols and other reducing agents,38 and therefore cell counting was 
selected as the preferred method to determine cell viability and obtain comparable data 
between the different cyclic-linear polymers. 
Internalization of the assemblies by A549 cells 
A549 cells were cultured as described in the previous paragraph. For the experiments, 
cells were seeded at a seeding density of 10000 cells/mL on EtOH sterilized circular glass 
slides (19 mm in diameter) placed on 12 wells plates. Cells were let adhere and proliferate for 
72 h. Culture medium was then replaced with 0.1 mg/mL or 0.3 mg/mL of polymer (cyclic or 
linear) encapsulating BODIPY-FL, diluted with the same F-12K (Kaighn’s) medium. Cells 
were incubated at 37 ˚C, 5% CO2 for 4 h, after which the medium was discarded and cells 
were washed with PBS (3 × 1 mL). Experiments were performed in triplicate. Cells were then 
fixed with a 4% paraformaldehyde solution in PBS for 10 min at room temperature, then 
washed with PBS (3 × 1 mL). Cells were then permeabilized with a solution of Triton X-100 
for 20 min at room temperature and washed with PBS (3 × 1 mL, 5 min each). Nuclei were 
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then stained with DAPI (15 µL in 20 mL of PBS) for 5 min, washed with PBS (3 × 1 mL) 
and finally stored in the dark at 4 ˚C overnight. Imaging was performed using a Zeiss LSM 
880 inverted confocal microscope. DAPI (λex = 358 nm, λem = 461 nm) was excited with a 
405 nm laser, and BODIPY-FL (λex = 503 nm, λem = 512 nm) with a 488 laser. At least ten 
pictures per glass slide were taken, covering the whole sample area. 
 
Results and discussion 
Amphiphilic cyclic-linear and linear-linear graft copolymers, 1 and 2, (Figure 1) were 
prepared as previously reported via a combination of ring-opening (ROP) and reversible 
addition-fragmentation chain transfer (RAFT) polymerization.30,32 Cyclization was achieved 
via copper-catalyzed azide-alkyne cycloaddition and utilized three different linking agents. 
The disulfide- and acetal-containing linkers were selected to introduce a reduction- and pH-
sensitive cleavable functionality to the cyclic polymer backbone (cyclic-linear graft 
copolymers 1i and 1ii, respectively). A non-responsive, alkyl linker, was also selected as a 
control for non-triggered disassembly (cyclic-linear graft copolymer 1iii). Graft copolymer 
arms were composed of poly(N-acryloylmorpholine) (PNAM), with degrees of 
polymerisation of ca. 19. As a result of experimental error, the molecular weights and 
dispersities of the polymers considered in this study vary between the different 
polymerisations performed, and hence the ratio between the hydrophobic and hydrophilic 
weight fractions may be different. Full characterization details for all of the polymers are 
available in the Supporting Information (Figures S1-S22 and Table S1). 
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Figure 1. (a) Cyclic-linear and linear-linear (1 and 2) PNAM graft copolymers, where 1 is 
cyclized with two responsive linkers to give 1i and 1ii and one non-responsive linker to give 
1iii; (b) Self-assembly of 1 in the presence of an imaging agent or a drug and subsequent 
particle disassembly and cargo release triggered by external stimuli (in the case of 1i and 1ii), 
to give cleaved linear graft copolymer 3. 
 
Self-assembly of PNAM cyclic-linear and linear-linear graft copolymers 1i (with the 
disulfide linkage) and 2, respectively, was studied with an emphasis on probing the relative 
stabilities of the assemblies. Three methods of polymer self-assembly were investigated; 
direct dissolution in water (18.2 MΩ·cm), solvent switch from THF to water and thin film 
hydration, all to give [polymer] = ca. 0.5 mg/mL. For assemblies of cyclic-linear graft 
copolymer 1i, well-defined aggregates with consistent values of Dh (150 - 170 nm) were 
produced each time (Table 1, Figure 2 and S23). In contrast, a large disparity in particle size 
was observed for linear-linear graft copolymer 2 for the different assembly techniques. Large 
structures (Dh > 100 nm) were observed for direct dissolution and solvent switch (Table 1, 
Figure 2 and S23), whereas small species consistent with unimers (Dh = 7 nm) were observed 
following thin film hydration, suggesting the absence of aggregation or that the resulting 
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assemblies were unstable (Table 1, Figure S23). Additionally, aggregates of linear-linear 
graft copolymer 2 exhibited significantly different particle sizes (Dh = 200-600 nm) and 
broader dispersities (PD ca. 0.4) for each repeat by DLS (Figure S23). The aggregates 
formation was further probed by determination of critical micelle concentration (cmc) 
(0.09 g/L for cyclic-linear graft copolymer 1i and 0.23 g/L for linear-linear graft copolymer 
2) (Table 1, Figure 2). However, while the cmc is indicative of the concentration at which the 
polymers aggregate, it gives no information on the stability and dynamic nature of the 
aggregation process. Thus, the stability of the particles to changes in polymer concentration 
was investigated by DLS. Assemblies of linear-linear graft copolymer 2 revealed a significant 
increase in Dh as [2] increased from 0.1 to 2 mg/mL (Figure S24). Meanwhile, assemblies of 
cyclic-linear graft copolymer 1i revealed very little difference in Dh over this concentration 
range (Figure S24). Assemblies of 1i and 2 were also monitored by DLS over time to gauge 
kinetic stability. After 48 h, assemblies of linear-linear graft copolymer 2 had disassembled to 
afford unimers with a Dh of ca. 7.5 nm (Figure 2). In contrast, assemblies of cyclic-linear 
graft copolymer 1 remained stable over a period of weeks; with no change in Dh or dispersity 
(Figure 2). SEC analysis confirmed the absence of graft copolymer degradation during this 
time period (Figure S25); therefore disassembly of linear-linear graft copolymer 2 under 
these conditions must result from poor particle stability and not polymer degradation. In 
combination, these findings strongly suggest that cyclic and linear polymers form assemblies 
of differing stability. Indeed, our results suggest that assemblies of cyclic-linear graft 
copolymer 1i possess both greater thermodynamic and kinetic stability than assemblies of 
linear-linear graft copolymer 2.  
 
Table 1. Characterization data for self-assemblies of cyclic-linear and linear-linear PNAM 
graft copolymers 1i and 2. 
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Polymer Dh (direct 
dissolution)/nm 
(PD)a 
Dh (solvent 
switch)/nm 
(PD)a 
Dh (thin film 
hydration)/nm (PD)a 
Daveb 
/nm 
Rgc 
/nm 
cmcd 
/g·L-1 
1i - cyclic 170 (0.15) 170 (0.56) 150 (0.28) 207 75 0.09 
2 - linear 200 (0.36) 115 (0.66) 7.1 (0.61) - 140 0.23 
aDetermined by DLS analysis, Dh is for number average solution diameters. bDetermined by cryo-TEM analysis 
from the counting of 50 particles, assemblies prepared by direct dissolution technique. cDetermined by SAXS 
analysis, assemblies prepared by direct dissolution technique. dDetermined by fluorescence spectroscopy using 
pyrene as the fluorescent probe, assemblies prepared by direct dissolution technique. 
  
Small angle X-ray scattering (SAXS) and cryogenic transmission electron microscopy 
(cryo-TEM) were undertaken to gain further insight into the size and morphology of the graft 
copolymer assemblies (Figure 2 and S26). The SAXS profiles (at 0.5 mg/mL) of both the 
cyclic-linear and linear-linear graft copolymers exhibited the same pattern, with a plateau 
region at medium q values and up-turn at low q values (Figure 2). The Guinier-Porod model 
was used to fit the SAXS data excluding high q values. In agreement with particle size 
determined by DLS analysis, an Rg of 75 nm was calculated for cyclic-linear graft copolymer 
1i, and an Rg of 140 nm was found for linear-linear graft copolymer 2. As was also observed 
by DLS analysis, the linear-linear graft exhibited a significantly larger dispersity than the 
cyclic-linear graft copolymer. Meanwhile, a Guinier plot (ln I(q) vs q2) was used to fit the 
SAXS data excluding the low q range, which gave Rg values of 3.7 and 3.3 nm for cyclic-
linear and linear-linear graft copolymers 1i and 2 respectively (Figure 2). As both large 
aggregates and unimers were observed in the linear-linear graft copolymer 2 by SAXS 
analysis, we suggest that a mixture of both is present in solution, indicative of a highly 
dynamic system. Cryo-TEM of cyclic-linear graft copolymer 1i at 2 mg/mL revealed large 
spherical structures with an average diameter of 207 ± 61 nm, in agreement with DLS and 
SAXS analyses (Figure S26).  Poor image contrast resulted from the high hydrophilic content 
of the assemblies and solvation of the PNAM corona. Cryo-TEM of linear-linear graft 
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copolymer 2 was attempted on numerous occasions, however no assemblies were observed, 
further suggestive of poor particle stability.  
  
Figure 2. DLS analysis showing assembly size for cyclic-linear and linear-linear PNAM 
graft copolymers 1i (a) and 2 (b) prepared via direct dissolution and their stability over time. 
(c) Concentration dependence of pyrene I339/I334.5 intensity ratio for assemblies 1i and 2. (d) 
SAXS profiles for assemblies of 1i and 2 at 0.5 mg/mL.  
 
Inspired by the observed differences in particle stability between assemblies of cyclic-
linear and linear-linear graft copolymers, we envisaged that a change in polymer topology, 
from cyclic to linear, could be exploited as a trigger for particle disassembly. Such a method 
of disassembly would avoid non-specific, random polymer degradation and the formation of 
side-products as the disassembled polymer and original polymer vary only in topology. 
Cyclic-linear graft copolymer 1i contains a disulfide moiety, which upon reduction induces 
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cleavage of the cyclic polymer backbone (Figure 1).  We reasoned that the relative instability 
of the resulting assemblies of linear graft copolymer 3 would result in particle disassembly. 
To test this hypothesis, the in vivo reducing agent L-glutathione (GSH) was added to a 
solution of aggregates of cyclic-linear graft copolymer 1i (0.5 mg/mL, Dh = 170 nm). At 
intracellular concentrations of GSH (1-10 mM), DLS analysis after 16 h revealed the 
complete loss of large self-assembled structures and the presence of only very small species 
with solution diameters that correspond to unimers (Dh = 7.4 nm, PD = 0.46) (Figure 3a); 
consistent with backbone cleavage to yield a linear graft copolymer, followed by disassembly 
of the relatively unstable particles. The newly formed linear graft copolymer 3 remained as a 
unimer and did not reassemble over time as determined by DLS analysis. Meanwhile, 
assemblies of cyclic-linear graft copolymer 1i in the presence of extracellular levels of GSH 
(1-10 µM) were observed to remain intact by DLS and did not disassemble over time (Figure 
S27). The transition from cyclic-linear graft copolymer aggregates to linear graft copolymer 
unimers was further studied by SAXS analysis over time and confirmed the disassembly of 
the particle under intracellular reducing conditions (Figure S27). Thus, as hypothesized, 
disulfide cleavage and particle disassembly are dependent on GSH concentration, which 
provides the opportunity for utilization of these constructs in specific triggered particle 
disassembly in intracellular environments.  
To confirm that the topology switch is the key trigger for disassembly, a second 
responsive linker was explored to provide a second topology switching nanoparticle. To 
achieve this an acid-sensitive acetal linker was designed and introduced as a cleavable moiety 
in the cyclic polymer structure, to give 1ii. The cyclic polymer based assembly 1ii (0.5 
mg/mL) was incubated in a solution at pH 4.0 for 100 h and degradation was monitored via 
DLS analysis. As expected, disassembly of the structure (with a decrease in particle size of 
210 nm to 6.5 nm) was observed after 100 h of incubation under these conditions, showing 
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that the topology change, from cyclic to linear, is independent of the cleavable linker selected 
or the conditions used (Figure 3c). Furthermore, when a non-responsive linker was used for 
the cyclization (to afford polymer 1iii), the topology switch from cyclic to linear did not 
occur, as no change in size was observed by DLS analysis upon incubation with 10 mM GSH 
(Figure 3b), while evidence of an increase in particle size, due to swelling of the assemblies, 
rather than disassembly was observed upon a reduction in pH (Figure 3d). This confirms that 
the topology change of the backbone from cyclic to linear (through incorporation of a 
cleavable linker) is required for nanoparticle disassembly. 
  
Figure 3. Aggregate disassembly triggered by disulfide cleavage of 1i with 10 mM L-
glutathione monitored by DLS before and 16 h after addition of GSH (a) and acetal cleavage 
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of 1ii with 0.1 mM HCl at pH 4.0 before and 100 h after addition of HCl (c), compared to 
non-responsive linker 1iii at the same conditions (b and d). Dh is volume average solution 
diameter.  
 
To demonstrate the applicability of this stimuli triggered topology switch for clinical and 
biological applications, we firstly tested the cytotoxicity of our cyclic-linear and linear-linear 
graft copolymers and their ability to be internalized by cancer cells. A549 cells were selected 
for this study as a model  cancer cell line with reported intracellular glutathione concentration 
higher than normal cells39-41. A549 (cancer lung fibroblasts) were incubated with increasing 
concentrations of cyclic-linear and linear-linear graft copolymers (from 0 to 2 mg/mL), and 
they showed a viability higher than 95% even at the highest concentration used (Figure S28), 
confirming the good cytocompatibility of the polymers. Furthermore, by encapsulating a 
fluorescent dye (BODIPY-FL) in both cyclic and linear polymer-based assemblies, we were 
able to track the particle’s uptake by A549 cells. All cyclic-linear graft copolymer 1 (1i - 1iii) 
and linear-linear copolymer 2 assemblies (0.1 mg/mL) were internalized by A549 within 4 h 
of incubation (Figure 4, and S29-30). However, when the linear assemblies 2 were incubated 
with A549 for 4 h, the fluorescent dye was found to remain as a precipitate on the glass slide 
even after extensive washings with PBS (Figure 4). This behavior was only observed with the 
linear-based assembly and not with any of the cyclic-linear graft copolymers, suggesting the 
linear-linear polymer disassembles much quicker than its cyclic-based counterpart. This 
result correlates well with our observation on the difference in stability of the cyclic and 
linear assemblies’ using scattering methods.  
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Figure 4. Internalization of cyclic 1i assemblies (a) and linear 2 assemblies (b) encapsulating 
Bodipy-FL (green) by A549 cells. (Inset, top right corner) Expansion of the image 
highlighting the absence (a) or presence (b) of precipitated dye on the glass slide. Images 
were taken after 4 h of incubation with the assemblies. Cell nuclei (blue) are stained with 
DAPI. Scale bar = 20 µm. 
  
Finally, to further exploit the scope of our topology-directed disassembly we loaded the 
assemblies of linear-linear and cyclic-linear NAM graft copolymers with an anti-cancer drug, 
camptothecin. Encapsulation efficiency (EE) was calculated as 70% for the cyclic-linear graft 
copolymers and 5% for the linear-linear graft copolymer assemblies, with a drug loading of 
0.14 mg of drug/1 mg of cyclic polymer and 0.01 mg drug/1 mg of linear polymer. Little 
variation was observed in encapsulation efficiency using the three different cyclic polymers, 
when 20% drug:polymer feeding ratio was used. The lower EE obtained for the linear 
assemblies can be explained by their lower stability and tendency to disassemble over time. 
A549 cells were incubated with both cyclic-linear (1i - 1iii) and linear-linear, 2, camptothecin 
loaded assemblies to investigate the effect of cleavage of the responsive linker, with 
subsequent release of the drug, upon uptake and exposure to the intracellular environment, 
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would have on the viability of the cancer cell line. Under these conditions, we confirmed the 
presence of aggregates of around 100 nm in diameter (Figure S31). 
As expected, a higher decrease in viability over time was observed when A549 cells were 
incubated with the cyclic-linear graft polymers containing a responsive linker (cyclic 1i and 
1ii) compared to the cyclic-linear graft polymer with the non-responsive linker (1iii), with a 
viability of 16 ± 3.0%, 35 ± 2.5% and 73 ± 8.7% for cyclic 1i, cyclic 1ii, and cyclic 1iii, 
respectively, when the camptothecin concentration is 250 nM (Figure 5 and S32). However, it 
should be noted that cyclic 1iii, containing the non-responsive linker, does induce 
cytotoxicity over time, with the cell viability decreasing below 40% after 72 h, when 
campothecin is encapsulated (Figure S32). In order to investigate if the cytotoxicity is a 
consequence of glutathione triggered release, a release study was conducted using 10 mM 
GSH as external stimulus. A 65% camptothecin release was observed from cyclic 1i, while 
no release was detected from cyclic 1iii (Figure S33). These data are in good agreement with 
the DLS study shown in Figure 3, where no disassembly was observed for cyclic 1iii using 10 
mM GSH. Therefore, the release of camptothecin from cyclic 1iii could be ascribed to either 
swelling, which indeed occurs at acidic pH (Figure 3d), or degradation of the polymer 
backbone in the cell environment and subsequent release, which has been reported before for 
polymeric nanoparticles with a degradable backbone42. 
In contrast, when A549 were incubated with the same concentration of linear-linear 
copolymer assemblies, 2, polymer viability was found to be higher than 95%, as a 
consequence of the lower amount of drug encapsulated (Figure S34).  
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Figure 5. Viability of A549 cells incubated for 24 h with increasing concentrations (from 0 to 
250 nM) of camptothecin encapsulated in the cyclic-linear graft copolymer assemblies (1i, 
1ii, and 1iii). 
 
Conclusions 
Herein, we have shown that self-assembled nanoparticles that are comprised of cyclic-
linear graft copolymers are significantly more stable, and are better able to encapsulate 
hydrophobic molecules, than their directly analogous (same chemistry) linear-linear 
equivalents. Subsequently, we have exploited the difference in assembly stability by 
switching between polymer topologies to direct the triggered disassembly of polymer 
nanoparticle constructs. In turn, we show that this approach can be used as to trigger the 
release of an anti-cancer drug in vitro using intracellular stimuli, such as intracellular 
glutathione concentration and acidic pH, to trigger the change in polymer topology. 
This study highlights, for the first time, that careful design of polymer topology and 
chemistry can be used to design novel delivery vehicles capable of triggered drug release. 
Indeed, we hypothesize that the cleavage of single bond within the polymer chain, which 
leads only to a change in topology of the core of the graft copolymer from cyclic to linear and 
subsequently facilitates nanoparticle disassembly, represents a new mechanism for controlled 
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release. Moreover, the simple change of one bond within the polymer structure ensures that 
the bulk of the chemical structure, molar mass and solubility are largely the same for both 
polymers before and after the delivery event which in turn should ensure that toxicity and 
retention characteristics of the polymer are unaltered. We believe that this is the first time that 
such a topology-driven switch has been reported and could have profound implications on the 
field of nanoparticle-mediate drug delivery.  
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